Welcome to industryreportstore.com

Need help? +44(0)20 7936 6830

Endocrinology & Metabolics market research, reports and industry analysis

mail

Contact us for professional industry advice

Email us or call

+44(0)20 7936 6830
mail

for FREE research alerts
to your inbox

10 Item(s)

Page 1 of 1

  1. Global Next-Generation Biologics Market 2016-2020

    By: Technavio
    , Published: Nov-2016
    , Product code: IRTNTR10904
    The report covers the present scenario and the growth prospects of the global next-generation biologics market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of next-generation biologics. The report also considers the revenues to be generated from the sales of drugs that are expected to be launched into the market during the forecast period.
    $2,500.00

  2. Global Metabolomic Technology Market Insights, Opportunity, Analysis, Market Shares And Forecast 2016 – 2022

    By: Occams Research
    , Published: Aug-2016
    , Product code: HAD-2710816
    The global metabolomics technology market is estimated to register robust growth in 2016- 2022 and is expected to grow at CAGR of 30.5% during 2016-2022. The metabolomics technology market is segmented on the basis of application, technique, indication and geography. The application segment is segmented into discovery & drug assessment, toxicology testing, biomarker discovery, nutrigenomics, and others. The technique segment is segmented into detection techniques and separation techniques. The indication segment is also segmented into cardiology, oncology, neurology and others. In indication segment cardiology accounts to large market share, the dominance is majorly driven by the increasing prevalence of cardiovascular diseases across the globe. Whereas the oncology segment is expected to grow with the high CAGR during the forecasted period 2016-2022.
    $3,900.00

  3. Global Endocrinology Drugs Market 2016-2020

    By: Technavio
    , Published: Apr-2016
    , Product code: IRTNTR9023
    The report covers the present scenario and the growth prospects of the global endocrinology drugs market for 2015-2020. To calculate the market size, the report considers revenue generated from the sales of branded drugs, generics, and biosimilars used to treat and prevent type 1 and type 2 diabetes, human growth hormone deficiency, hypogonadism, and thyroid gland disorders.
    $2,500.00

  4. Global Metabolomics Market Insights, Opportunity Analysis, Market Shares and Forecast 2016 – 2022

    By: Occams Research
    , Published: Apr-2016
    , Product code: HME-1591015
    Metabolomics can be defined as the study of metabolites or low molecular weight molecules found inside the cells and the biological systems. This branch of science basically aims at the comparison finding out the differences between biological samples and is based on their metabolite profile. Metabolomics generally makes the use of analytical process like Chromatography, spectroscopy and multi variable analysis.
    $3,900.00

  5. Global Endocrine Testing Market 2015-2019

    By: Technavio
    , Published: Jun-2015
    , Product code: IRTNTR6125
    TechNavio's report, Global Endocrine Testing Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
    $3,000.00

  6. PharmaPoint: Dyslipidemia - Global Drug Forecast and Market Analysis to 2023

    By: GlobalData
    , Published: May-2015
    , Product code: GDHC110PIDR
    GlobalData estimates that the total market size for the 8MM in 2013 was $15.4bn, comprised of $11.0bn in branded drug sales (72%) and $4.4bn in generic sales (28%). GlobalData expects that the dyslipidemia drug market will grow at a CAGR of 9.4% over the ten year forecast period, resulting in a market value of $37.9bn by 2023, of which 71% will be attributed to branded drug sales ($26.9bn) and 29% to generic drug sales ($11.0bn). The current dyslipidemia market is dominated by the statins, the revolutionary drugs that reduce low-density lipoprotein cholesterol (LDL-C) and that have been proven to reduce the risk of cardiovascular events such as heart attack and stroke. Other major lipid-modulating drugs, such as Zetia (ezetimibe), the fibrates, bile acid sequestrants, omega-3 fish oil agents, and rare-disease therapies comprise the remainder of the current dyslipidemia space. The launch of the proprotein convertase subtilisin/kexin type 9 (PCSK9) biologics and the cholesteryl ester transfer protein (CETP) inhibitors will reshape the sales landscape of the dyslipidemia market moving forward.
    $10,995.00

  7. Hyperglycemia - Pipeline Review, H2 2014

    By: Global Markets Direct
    , Published: Sep-2014
    , Product code: GMDHC5515IDB
    This report provides comprehensive information on the therapeutic development for Hyperglycemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hyperglycemia and special features on late-stage and discontinued projects.
    $2,000.00

  8. Diabetic Neuropathy - Pipeline Review, H2 2014

    By: Global Markets Direct
    , Published: Aug-2014
    , Product code: GMDHC5375IDB
    This report provides comprehensive information on the therapeutic development for Diabetic Neuropathy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diabetic Neuropathy and special features on late-stage and discontinued projects.
    $2,000.00

  9. Amyloidosis - Pipeline Review, H2 2014

    By: Global Markets Direct
    , Published: Aug-2014
    , Product code: GMDHC5390IDB
    This report provides comprehensive information on the therapeutic development for Amyloidosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Amyloidosis and special features on late-stage and discontinued projects.
    $2,000.00

  10. Global Metabolomics Market 2014-2018

    By: Technavio
    , Published: Jul-2014
    , Product code: IRTNTR3797
    About Metabolomics Metabolomics or Metabonomics is the scientific study of chemical processes involving metabolites. Metabolomics has become a new experimental technique that is being widely used in biology, medicine and the environmental sciences. Metabolites are small molecules that are present in blood, urine, and tissues. The pattern, or fingerprint, of metabolites in a biological sample is used to learn about the health of organisms. The unique patterns of metabolites are widely used to diagnose specific diseases. A metabolome is the terminology used in metabolomics to describe the comprehensive and quantitative analysis of all the metabolites of an organism. Metabolomics is a relatively new field of omics research compared to other similar fields such as genomics, proteomics, and transcriptomics.
    $2,500.00

10 Item(s)

Page 1 of 1